Home・Elenco Azioni・Boston Scientific Corp.

Boston Scientific Corp.

Chiusa

SettoreSettore sanitario

51.81 0.12

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

51.68

Massimo

52.75

Metriche Chiave
By Trading Economics
Entrata	-437M 904M
Vendite	239M 5.4B
P/E Media del settore	19.945 57.002
EPS	0.86
Margine di Profitto	16.612
Dipendenti	59,000
EBITDA	-214M 1.4B

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+20.41% upside

Dividendi
By Acuity
Utili prossimi	28 ott 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	5.5B 73B
Apertura precedente	51.69
Chiusura precedente	51.81

Notizie sul Sentiment di mercato

By Acuity

41%

59%

144 / 340 Classifica in Healthcare

Boston Scientific Corp. Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

14 ago 2026, 23:01 UTC

Boston Scientific Corp shares are higher in after-market trading, continuing a trend of six consecutive sessions finishing higher. No specific news was identified.

13 ago 2026, 23:01 UTC

Social Media

Boston Scientific shares are higher in after-market trading, buoyed by social media discussions of the CEO's $9 million stock purchase amid a significant year-to-date decline.

12 ago 2026, 23:06 UTC

Boston Scientific Corp shares are modestly higher in after-market trading. The stock remains significantly above its 20-day moving average.

11 ago 2026, 23:41 UTC

Boston Scientific Corp shares are lower in after-market trading, showing unusual volatility and reflecting a broader trend of weakness since Tuesday's close.

10 ago 2026, 23:06 UTC

Boston Scientific shares are trading higher in after-market hours, amid mixed market sentiment influenced by geopolitical tensions, particularly concerning the Strait of Hormuz.

8 ago 2026, 00:01 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting gains since Friday's close and remaining above their 20-day moving average.

7 ago 2026, 23:21 UTC

Boston Scientific shares are higher in after-market hours following a Labor Department report showing a decline in non-farm payroll employment, reducing interest rate hike expectations.

6 ago 2026, 23:01 UTC

Boston Scientific Corp shares are higher during after-market hours, reflecting a generally strong performance backdrop amid resilient labor market data.

5 ago 2026, 23:02 UTC

Social Media

News

Boston Scientific Corp shares rose in after-market trading following CEO Mahoney's purchase of 186,240 shares at an average price of $48.33.

4 ago 2026, 19:36 UTC

News

Boston Scientific shares are higher, supported by strong organic revenue growth and rising free cash flow margin, despite recent economic data pressures.

3 ago 2026, 23:01 UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting positive momentum. Broader economic news shows increased growth in the manufacturing sector.

31 lug 2026, 22:52 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting positive market sentiment from strong earnings by major tech companies.

30 lug 2026, 23:51 UTC

News

Boston Scientific shares are higher in after-market trading following UBS's Buy rating and a price target adjustment to $67 amid Penumbra's results.

29 lug 2026, 23:51 UTC

Boston Scientific Corp shares are higher in after-market trading, reflecting broader market gains. No specific news has been identified to explain the movement.

28 lug 2026, 23:52 UTC

Boston Scientific Corp shares are higher in after-market hours, reflecting a steady increase since Tuesday's close despite broader market concerns, particularly in Asia.

27 lug 2026, 23:02 UTC

News

Social Media

Boston Scientific plans a restructuring with pre-tax charges of $700 million to $800 million, leading shares lower in after-market hours.

25 lug 2026, 00:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

24 lug 2026, 23:01 UTC

News

Boston Scientific shares are higher in after-market hours despite a safety alert from the FDA regarding its ENROUTE Transcarotid Neuroprotection System catheters.

22 lug 2026, 20:06 UTC

Correlated Moves

Boston Scientific reported first-quarter adjusted EPS of $0.43, missing estimates. Shares are trading lower amid cautious market sentiment and Stryker's decline.

21 lug 2026, 23:06 UTC

Boston Scientific Corp shares are higher in after-hours trading, reflecting a modest uptick following Tuesday's close. The stock remains below its 20-day moving average.

20 lug 2026, 23:01 UTC

Boston Scientific shares are higher in after-market trading, reflecting notable strength since Monday's close, despite no specific news driving the movement.

Confronto tra pari

Modifica del prezzo

Boston Scientific Corp. Previsione

Obiettivo di Prezzo

By TipRanks

20.41% in crescita

Previsioni per 12 mesi

Media 62.41 USD 20.41%

Alto 89 USD

Basso 50 USD

Basato su 24 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Boston Scientific Corp. - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

24 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 24 che hanno fornito valutazioni azionarie a Boston Scientific Corp. - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

144 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Boston Scientific Corp.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.